Core Viewpoint - The article discusses the strategic market operations of Haixi New Drug (02637) over the past two months, highlighting a well-planned effort to increase market capitalization and liquidity in preparation for inclusion in the Hong Kong Stock Connect program [1][11]. Group 1: Market Operation Phases - The market operation can be divided into four distinct phases aimed at enhancing and stabilizing market capitalization to meet the Hong Kong Stock Connect inclusion criteria [3][11]. Phase 1: Accumulation - From October 20 to October 30, the stock price rose from 97.50, increasing by 18.63% over eight trading days, with a significant trading volume of 379.17 million shares and a turnover rate of 4.82% [3][4]. - The buying pressure was dominant, with 87.5% of the trading volume being positive, indicating strong accumulation by the main players [3][4]. Phase 2: Technical Adjustment - From October 31 to November 5, the stock experienced a 5.79% pullback with a drastic reduction in trading volume to 47.87 million shares and a turnover rate of only 0.61% [5][6]. - This phase was characterized by a "volume contraction" strategy to clear short-term floating positions and raise the average market holding cost [5]. Phase 3: Breakthrough - From November 6 to November 12, the stock surged from 112.50 to 147.00, marking a 26.49% increase with a low turnover rate of 0.79% and 100% of the trading volume being positive [7][8]. - This indicates a high level of control by the main players, allowing for a rapid price increase with minimal capital outlay [7]. Phase 4: Consolidation - From November 13 to December 9, the stock underwent a period of consolidation around a new price level, maintaining an average price of 130.54, with more positive trading days than negative [9][10]. - This consolidation phase is crucial for building market consensus and preparing for further market capitalization expansion [9]. Group 2: Market Capitalization Strategy - Haixi New Drug has submitted an application for "full circulation" of shares, which will allow major shareholders to sell their shares in the secondary market after a 12-month lock-up period, enhancing the motivation for active market capitalization management [12]. - The company aims to exceed the minimum daily market capitalization requirement of 9.3 billion HKD to qualify for the Hong Kong Stock Connect program, with a current average market capitalization of 9.77 billion HKD as of December 10 [12][13]. - The strategy is designed to secure a "market capitalization safety cushion" by significantly increasing market value at the beginning of the assessment period, thus reducing the risk of falling below the required threshold [12][13].
冲刺港股通终检窗口：海西新药(02637)的“市值安全垫”与盘面语言